NOD1 and colorectal carcinoma: Intriguingly, NLR agonists, specially NOD1 and NOD2 agonists, have been proposed as therapeutic agents in CRC treatment because both experimental studies showed that NOD1 deficiency leads to increased tumorigenesis in mice (142) and the activation of these NLR may regulate the pro-inflammatory effects induced by other PRR (143, 144).